The World Health Organization (WHO) announced on Monday that a breakthrough HIV drug should be made available ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

The World Health Organization (WHO) has issued new guidelines recommending the twice-yearly use of injectable lenacapavir ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The future of the global HIV response risks being undermined by shrinking funding and wavering political will, health leaders have warned as the International AIDS Society (IAS) Conference on HIV ...

Global health leaders and advocates challenged attendees of IAS to support the work of the partnerships that are creating patient-focused innovations for HIV prevention and treatment.

The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according to a press release .

The World Health Organisation (WHO) has for the first time recommended the use of injectable lenacapavir (LEN) as a ...